Search
for
Sort by
Research 31–60 of 554
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Ritlecitinib (Litfulo)
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study
- 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
- P165 Real-world experience of ritlecitinib for the treatment of alopecia areata from an alopecia clinic in a large tertiary dermatology centre
- P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
- BH31 Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib